News


Lenco Diagnostic Laboratories Launches IgG and IgM Serology Testing to Detect Antibodies Against COVID-19

Brooklyn, NY (April 16, 2020) - Lenco Diagnostic Laboratories (Lenco), one of NYC's largest independently owned full-service clinical laboratories, today announced the launch of antibody testing for coronavirus (COVID-19).

“In the last several weeks, Lenco has been diligently working with trusted partners to launch a test that will detect the presence of IgG and IgM antibodies produced by the body in response to the SARS-CoV-2 virus,” stated Dennis Tilman, Chief Operating Officer of Lenco. “We are hopeful the knowledge obtained from these tests will help both physicians and patients in the management and care of this novel virus. Lenco is proud to expand its diagnostic capabilities and will continue to contribute to the needs of the community.”

The Advantages of Molecular Testing for the Flu

October marks the beginning of flu season.  As in previous years, flu cases are expected to peak between December and February, and taper off around May.   While most cases of the “flu” are diagnosed and treated empirically, based on the common symptoms with which it usually presents (fever, headache, sore throat, cough, runny nose, as well as body aches being the most common ones), this is obviously not a 100% accurate method of diagnosis. Instead, physicians should consider using molecular influenza assays to get an accurate diagnosis, especially in the case of patients with complications.

Load more posts